Page 116 - Read Online

Offin et al. J Cancer Metastasis Treat 2023;9:21 https://dx.doi.org/10.20517/2394-4722.2022.140 Page 13 of 16

PubMed
26. Leal JL, Peters G, Szaumkessel M, et al. NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary
neuroendocrine tumours and non-small cell lung cancer. Lung Cancer 2020;146:154-9. DOI
27. Chen Y, Chen B, Zhu X, Zhong J. A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to
vemurafenib. Lung Cancer 2018;116:96-8. DOI
28. Rüschoff JH, Gradhand E, Kahraman A, et al. STRN-ALK rearranged malignant peritoneal mesothelioma with dramatic response
following ceritinib treatment. JCO Precis Oncol 2019:3. DOI PubMed PMC
29. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76. DOI PubMed
30. National Comprehensive Cancer Network. Malignant pleural mesothelioma (version 1.2023). Available from: https://www.nccn.org/
professionals/physician_gls/pdf/mpm.pdf [Last accessed on 31 May 2023].
31. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin
Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:1405-14. DOI
32. Zauderer MG. A new standard for malignant pleural mesothelioma. Lancet 2016;387:1352-4. DOI PubMed PMC
33. Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities
and challenges. Nat Rev Clin Oncol 2018;15:325-40. DOI PubMed PMC
34. Pinto C, Zucali PA, Pagano M, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural
mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2021;22:1438-47. DOI
35. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007;18:985-90. DOI PubMed
36. Hiltbrunner S, Fleischmann Z, Sokol ES, Zoche M, Felley-Bosco E, Curioni-Fontecedro A. Genomic landscape of pleural and
peritoneal mesothelioma tumours. Br J Cancer 2022;127:1997-2005. DOI PubMed PMC
37. Raghav K, Liu S, Overman MJ, et al. Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizumab) and VEGF
(Bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov 2021;11:2738-47. DOI PubMed PMC
38. Tsao AS, Miao J, Wistuba II, et al. SWOG S0905: a randomized phase II study of cediranib versus placebo in combination with
cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma. J Clin Oncol 2018;36:8514-8514. DOI
39. Tsao AS, Miao J, Wistuba II, et al. Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naïve
patients with unresectable malignant pleural mesothelioma (SWOG S0905). J Clin Oncol 2019;37:2537-47. DOI PubMed PMC
40. Campbell NP, Kunnavakkam R, Leighl N, et al. Cediranib in patients with malignant mesothelioma: a phase II trial of the University
of Chicago Phase II Consortium. Lung Cancer 2012;78:76-80. DOI PubMed PMC
41. Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients
with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet
Respir Med 2019;7:569-80. DOI
42. Wozniak AJ, Schneider BJ, Kalemkerian GP, et al. A phase II trial of nintedanib in recurrent malignant pleural mesothelioma
(MPM). J Clin Oncol 2019;37:e20061-e20061. DOI
43. Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 2014;74:2907-12. DOI
PubMed PMC
44. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000;20:2902-6. DOI
PubMed
45. Hu ZI, Ghafoor A, Sengupta M, Hassan R. Malignant mesothelioma: advances in immune checkpoint inhibitor and mesothelin-
targeted therapies. Cancer 2021;127:1010-20. DOI PubMed PMC
46. Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and
cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res 2014;20:5927-36. DOI PubMed PMC
47. Leshem Y, King EM, Mazor R, Reiter Y, Pastan I. SS1P immunotoxin induces markers of immunogenic cell death and enhances the
effect of the CTLA-4 blockade in AE17M mouse mesothelioma tumors. Toxins 2018;10:470. DOI PubMed PMC
48. Hassan R, Sharon E, Thomas A, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and
cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte
potentiating factor, and cancer antigen 125. Cancer 2014;120:3311-9. DOI PubMed PMC
49. Hassan R, Miller AC, Sharon E, et al. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin
and immune suppression. Sci Transl Med 2013;5:208ra147. DOI PubMed PMC
50. Bauss F, Lechmann M, Krippendorff BF, et al. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin
fusion protein for lung cancer therapy. Mol Oncol 2016;10:1317-29. DOI PubMed PMC
51. Hassan R, Alewine C, Mian I, et al. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid
tumors expressing mesothelin. Cancer 2020;126:4936-47. DOI PubMed PMC
52. Molloy ME, Austin RJ, Lemon BD, et al. Preclinical Characterization of HPN536, a trispecific, T-cell-activating protein construct for
the treatment of mesothelin-expressing solid tumors. Clin Cancer Res 2021;27:1452-62. DOI
53. Golfier S, Kopitz C, Kahnert A, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with
heterogeneous target expression favored by bystander effect. Mol Cancer Ther 2014;13:1537-48. DOI PubMed
54. Hassan R, Blumenschein GR Jr, Moore KN, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-
mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors. J Clin Oncol 2020;38:1824-35.
DOI PubMed